Search

everythinglearnresearchcommunity

for

Search:↓

The user is concerned about hair loss and is hesitant to use treatments like finasteride and minoxidil due to potential side effects. Another user suggests gradually introducing finasteride to minimize side effects and maximize results.

The conversation discusses the impact of hair loss treatments like dutasteride and finasteride, with some users expressing skepticism about media claims linking these drugs to severe side effects like suicidal ideation. Many participants criticize the media, particularly British tabloids, for fearmongering and emphasize the psychological impact of hair loss itself.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

The user regrets stopping finasteride and minoxidil due to increased hair loss. They have resumed these treatments and are considering a hair transplant.

The user shared their positive experience with hair loss treatment using minoxidil and finasteride over seven years, noting significant improvement and satisfaction despite some inconsistency with finasteride dosage. They reported minimal side effects, with a slight initial decrease in libido that later adjusted.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Hair loss is distressing, with treatments like finasteride, minoxidil, and spironolactone commonly used despite potential side effects. Emphasis is placed on maintaining mental health and self-worth beyond hair appearance.

Dutasteride and finasteride for hair loss, with dissatisfaction expressed about dutasteride and consideration of switching back to finasteride. Users share varied experiences, noting individual responses to treatments differ.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

The conversation discusses using Pyrilutamide 1% as a potential treatment for hair loss, with some users combining it with minoxidil and finasteride. Experiences vary, with some reporting shedding and no progress, while others remain hopeful for future results.

Stopping minoxidil causes significant hair loss, as continued use is necessary for maintaining gains. Combining minoxidil with finasteride may help maintain hair, but both treatments are typically lifelong commitments.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation discusses using crushed finasteride tablets mixed with topical minoxidil for hair loss treatment. Users share their experiences and opinions on the effectiveness and proper concentration of this method.

The conversation discusses various celebrities who reportedly use hair loss treatments like finasteride and dutasteride. Users share their experiences and opinions on starting treatment, with some encouraging the original poster to consult a dermatologist and consider treatment before it's too late.

The conversation discusses why personal stories about hair loss treatments like Minoxidil and finasteride are often taken more seriously than scientific evidence in certain forums. People tend to believe what they want and use others' experiences to support their own views on treatment effectiveness and side effects.

Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The user is using minoxidil and recently started fluridil for mild hair loss and is questioning if this treatment is sufficient without finasteride. They have finasteride available but prefer not to use it.

A user is considering a long-term hair loss treatment stack including Dutasteride, Finasteride, and oral Minoxidil, and is concerned about potential liver damage. Some responses suggest the stack is excessive, while others believe it's not harmful to the liver, but recommend regular blood work to monitor health.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

The conversation compares Finasteride and Dutasteride for hair loss treatment, discussing their effectiveness and side effects. Users share personal results and consider combining treatments like Dutasteride with RU58841.

Minoxidil can regrow hair but doesn't address the underlying issue of DHT, leading to continued hair loss. Users discuss their experiences with finasteride and dutasteride, mentioning side effects, personal outcomes, and alternatives like microdosing topical finasteride.

A user shared a 3.5-month hair loss treatment progress using topical Minoxidil, Finasteride, and RU58841, noting improved confidence and satisfaction with the results. Other users congratulated and praised the progress shown in the pictures.